Efficacy and tolerability of dronedarone for patients with atrial fibrillation

Tonye Teme, Jeffrey Goldberger

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF). We investigate its efficacy and tolerability in clinical practice. Methods: We identified 208 patients treated with dronedarone for AF at the Northwestern outpatient practice. Charts were reviewed for clinical efficacy and reasons for discontinuation of the drug. Results: The average age was 65.2 ± 10.8 years, 37% females. Paroxysmal, persistent and permanent AF were noted in 46.2%, 51.9%, and 1.9%, respectively. Average ejection fraction was 56.3 ± 9.1%, 12.8% had a history of congestive heart failure, and 10.3% had valvular heart disease. Dronedarone was discontinued in 25 patients after curative catheter or surgical ablation procedure. Of the remaining 183 patients, dronedarone was discontinued in 48.6% after a mean duration of 6.2 ± 6.3 months because of inefficacy (26.2%), side effects (6%), and other reasons (16.4%). For those remaining on dronedarone (n = 94), after a mean of 11.6 ±6.6 months, clinical efficacy (resolution of or patient-reported improvement in symptoms) was noted in 45.4% patients. On dronedarone therapy, 57.4% had no AF on follow-up (overall efficacy of 29.5%). To evaluate efficacy, ECG only or long-term monitoring were performed in 62.7% and 37.3%, respectively, and found no AF in 69.2 and 48.4%, respectively. There were 3 deaths and 2 transient ischemic attacks (TIA) off dronedarone vs. 1 death, 1 TIA and 2 strokes on dronedarone. Conclusions: Dronedarone has a significant discontinuation rate due to both inefficacy and side effects in clinical practice. Nevertheless, it has moderate clinical efficacy and tolerability in an outpatient population of patients with AF.

Original languageEnglish (US)
Pages (from-to)486-490
Number of pages5
JournalCardiology Journal
Volume20
Issue number5
DOIs
StatePublished - Oct 15 2013
Externally publishedYes

Fingerprint

Atrial Fibrillation
Transient Ischemic Attack
Outpatients
dronedarone
Heart Valve Diseases
Anti-Arrhythmia Agents
Electrocardiography
Catheters
Heart Failure
Stroke
Therapeutics
Pharmaceutical Preparations
Population

Keywords

  • Atrial fibrillation
  • Dronedarone
  • Efficacy
  • Tolerability

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and tolerability of dronedarone for patients with atrial fibrillation. / Teme, Tonye; Goldberger, Jeffrey.

In: Cardiology Journal, Vol. 20, No. 5, 15.10.2013, p. 486-490.

Research output: Contribution to journalArticle

@article{8895754db6ec4d599c0642305ad8dd45,
title = "Efficacy and tolerability of dronedarone for patients with atrial fibrillation",
abstract = "Background: Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF). We investigate its efficacy and tolerability in clinical practice. Methods: We identified 208 patients treated with dronedarone for AF at the Northwestern outpatient practice. Charts were reviewed for clinical efficacy and reasons for discontinuation of the drug. Results: The average age was 65.2 ± 10.8 years, 37{\%} females. Paroxysmal, persistent and permanent AF were noted in 46.2{\%}, 51.9{\%}, and 1.9{\%}, respectively. Average ejection fraction was 56.3 ± 9.1{\%}, 12.8{\%} had a history of congestive heart failure, and 10.3{\%} had valvular heart disease. Dronedarone was discontinued in 25 patients after curative catheter or surgical ablation procedure. Of the remaining 183 patients, dronedarone was discontinued in 48.6{\%} after a mean duration of 6.2 ± 6.3 months because of inefficacy (26.2{\%}), side effects (6{\%}), and other reasons (16.4{\%}). For those remaining on dronedarone (n = 94), after a mean of 11.6 ±6.6 months, clinical efficacy (resolution of or patient-reported improvement in symptoms) was noted in 45.4{\%} patients. On dronedarone therapy, 57.4{\%} had no AF on follow-up (overall efficacy of 29.5{\%}). To evaluate efficacy, ECG only or long-term monitoring were performed in 62.7{\%} and 37.3{\%}, respectively, and found no AF in 69.2 and 48.4{\%}, respectively. There were 3 deaths and 2 transient ischemic attacks (TIA) off dronedarone vs. 1 death, 1 TIA and 2 strokes on dronedarone. Conclusions: Dronedarone has a significant discontinuation rate due to both inefficacy and side effects in clinical practice. Nevertheless, it has moderate clinical efficacy and tolerability in an outpatient population of patients with AF.",
keywords = "Atrial fibrillation, Dronedarone, Efficacy, Tolerability",
author = "Tonye Teme and Jeffrey Goldberger",
year = "2013",
month = "10",
day = "15",
doi = "10.5603/CJ.2013.0133",
language = "English (US)",
volume = "20",
pages = "486--490",
journal = "Cardiology Journal",
issn = "1897-5593",
publisher = "Via Medica",
number = "5",

}

TY - JOUR

T1 - Efficacy and tolerability of dronedarone for patients with atrial fibrillation

AU - Teme, Tonye

AU - Goldberger, Jeffrey

PY - 2013/10/15

Y1 - 2013/10/15

N2 - Background: Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF). We investigate its efficacy and tolerability in clinical practice. Methods: We identified 208 patients treated with dronedarone for AF at the Northwestern outpatient practice. Charts were reviewed for clinical efficacy and reasons for discontinuation of the drug. Results: The average age was 65.2 ± 10.8 years, 37% females. Paroxysmal, persistent and permanent AF were noted in 46.2%, 51.9%, and 1.9%, respectively. Average ejection fraction was 56.3 ± 9.1%, 12.8% had a history of congestive heart failure, and 10.3% had valvular heart disease. Dronedarone was discontinued in 25 patients after curative catheter or surgical ablation procedure. Of the remaining 183 patients, dronedarone was discontinued in 48.6% after a mean duration of 6.2 ± 6.3 months because of inefficacy (26.2%), side effects (6%), and other reasons (16.4%). For those remaining on dronedarone (n = 94), after a mean of 11.6 ±6.6 months, clinical efficacy (resolution of or patient-reported improvement in symptoms) was noted in 45.4% patients. On dronedarone therapy, 57.4% had no AF on follow-up (overall efficacy of 29.5%). To evaluate efficacy, ECG only or long-term monitoring were performed in 62.7% and 37.3%, respectively, and found no AF in 69.2 and 48.4%, respectively. There were 3 deaths and 2 transient ischemic attacks (TIA) off dronedarone vs. 1 death, 1 TIA and 2 strokes on dronedarone. Conclusions: Dronedarone has a significant discontinuation rate due to both inefficacy and side effects in clinical practice. Nevertheless, it has moderate clinical efficacy and tolerability in an outpatient population of patients with AF.

AB - Background: Dronedarone is a new antiarrhythmic drug used in the treatment of atrial fibrillation (AF). We investigate its efficacy and tolerability in clinical practice. Methods: We identified 208 patients treated with dronedarone for AF at the Northwestern outpatient practice. Charts were reviewed for clinical efficacy and reasons for discontinuation of the drug. Results: The average age was 65.2 ± 10.8 years, 37% females. Paroxysmal, persistent and permanent AF were noted in 46.2%, 51.9%, and 1.9%, respectively. Average ejection fraction was 56.3 ± 9.1%, 12.8% had a history of congestive heart failure, and 10.3% had valvular heart disease. Dronedarone was discontinued in 25 patients after curative catheter or surgical ablation procedure. Of the remaining 183 patients, dronedarone was discontinued in 48.6% after a mean duration of 6.2 ± 6.3 months because of inefficacy (26.2%), side effects (6%), and other reasons (16.4%). For those remaining on dronedarone (n = 94), after a mean of 11.6 ±6.6 months, clinical efficacy (resolution of or patient-reported improvement in symptoms) was noted in 45.4% patients. On dronedarone therapy, 57.4% had no AF on follow-up (overall efficacy of 29.5%). To evaluate efficacy, ECG only or long-term monitoring were performed in 62.7% and 37.3%, respectively, and found no AF in 69.2 and 48.4%, respectively. There were 3 deaths and 2 transient ischemic attacks (TIA) off dronedarone vs. 1 death, 1 TIA and 2 strokes on dronedarone. Conclusions: Dronedarone has a significant discontinuation rate due to both inefficacy and side effects in clinical practice. Nevertheless, it has moderate clinical efficacy and tolerability in an outpatient population of patients with AF.

KW - Atrial fibrillation

KW - Dronedarone

KW - Efficacy

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84885224882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885224882&partnerID=8YFLogxK

U2 - 10.5603/CJ.2013.0133

DO - 10.5603/CJ.2013.0133

M3 - Article

C2 - 24469871

AN - SCOPUS:84885224882

VL - 20

SP - 486

EP - 490

JO - Cardiology Journal

JF - Cardiology Journal

SN - 1897-5593

IS - 5

ER -